1. Home
  2. AIDX vs RFL Comparison

AIDX vs RFL Comparison

Compare AIDX & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIDX

20/20 Biolabs Inc. Common Stock

N/A

Current Price

$1.92

Market Cap

58.8M

Sector

Health Care

ML Signal

N/A

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.28

Market Cap

61.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIDX
RFL
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
58.8M
61.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
AIDX
RFL
Price
$1.92
$1.28
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
280.5K
103.3K
Earning Date
N/A
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.28
EPS
N/A
N/A
Revenue
N/A
$917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.96
52 Week Low
$1.87
$1.12
52 Week High
$14.09
$3.19

Technical Indicators

Market Signals
Indicator
AIDX
RFL
Relative Strength Index (RSI) 4.91 45.22
Support Level N/A $1.15
Resistance Level $3.08 $1.38
Average True Range (ATR) 0.44 0.14
MACD 0.02 -0.02
Stochastic Oscillator 7.05 11.11

Price Performance

Historical Comparison
AIDX
RFL

About AIDX 20/20 Biolabs Inc. Common Stock

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: